On March 25, the U.S. Food and Drug Administration (FDA) approved the first new antibiotic to treat UTIs in 30 years. The medication, gepotidacin, targets E. coli bacteria, which is responsible for ...

The US Food and Drug Administration has approved a new type of antibiotic to treat urinary tract infections. The pill, gepotidacin, will be sold under the brand name Blujepa and is expected to be ...

Blujepa, the first new oral UTI antibiotic in 30 years, offers hope against antibiotic-resistant infections, improving treatment options for millions of women.

The U.S. Food and Drug Administration (FDA) has approved GSK’s Blujepa (gepotidacin), a groundbreaking oral antibiotic for treating uncomplicated urinary tract infections (uUTIs) in adult women and ...

The FDA has approved Blujepa (gepotidacin) for the treatment of female patients 12 years of age and older weighing at least 40kg with uncomplicated UTI.

Fact checked by Nick Blackmer The Food and Drug Administration (FDA) recently approved a new antibiotic to treat urinary tract infections (UTIs). The drug gepotidacin, which will be sold under the ...

The Food and Drug Administration (FDA) has approved a new drug, Blujepa, the first of a new class of oral antibiotics for treating UTIs, to head to market. Drugmaker GSK plans to release the ...

The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...

TUESDAY, March 25, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Blujepa (gepotidacin) for the treatment of uncomplicated urinary tract infections (uUTIs) in adult ...

GSK (LSE:GSK) recently announced the FDA approval of Blujepa, a first-in-class antibiotic for urinary tract infections, and ...

“The approval of Blujepa is a crucial milestone with uUTIs among the most common infections in women,” said Tony Wood, Chief Scientific Officer, GSK. “We are proud to have developed ...